Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice

American Journal of Respiratory Cell and Molecular Biology

Volumn 49, Issue 6, 2013, Pages 912-922

  Huang, Long Shuang ^a   Fu, Panfeng ^a   Patel, Priya ^a   Harijith, Anantha ^b   Sun, Tianjiao ^c   Zhao, Yutong ^d   Garcia, Joe G N ^a   Chun, Jerold ^e   Natarajan, Viswanathan ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Idiopathic pulmonary fibrosis; LPA2; Lysophosphatidic acid; Transforming growth factor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; COLLAGEN; FIBRONECTIN; INTERLEUKIN 6; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN; PROTEIN KINASE B; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROGENESIS; GENE SILENCING; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG INJURY; LUNG PARENCHYMA; LUNG PROTECTION; MALE; MORTALITY; MOUSE; MYOFIBROBLAST; NONHUMAN; PATHOGENESIS; PNEUMONIA; PROTECTION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ACTINS; ANIMALS; APOPTOSIS; BLEOMYCIN; CELL DIFFERENTIATION; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROBLASTS; FIBRONECTINS; GENE KNOCKDOWN TECHNIQUES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG INJURY; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, LYSOPHOSPHATIDIC ACID; TRANSFORMING GROWTH FACTOR BETA;

EID: 84890091865     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2013-0070OC     Document Type: Article

References (50)

1. King TE Jr. Update in pulmonary medicine. Ann Intern Med 1998;129:806-812.
2. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, Hayes J, Sillery JK, Pope CE II, Pellegrini CA. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006;27:136-142.
3. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D. NAD (P) H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005;97:900-907.
4. Sappino AP, Schurch W, Gabbiani G. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab Invest 1990;63:144-161.
5. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002;122(Suppl. 6):286S-289S.
6. Phan SH, Zhang K, Zhang HY, Gharaee-Kermani M. The myofibroblast as an inflammatory cell in pulmonary fibrosis. Curr Top Pathol 1999;93:173-182.
7. Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/ fibroblastic cross-talk disorder. Respir Res 2002;3:3.
8. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151.
9. Fahim A, Crooks M, Hart SP. Gastroesophageal reflux and idiopathic pulmonary fibrosis: a review. Pulm Med 2011;2011:634613.
10. Watterson KR, Lanning DA, Diegelmann RF, Spiegel S. Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing. Wound Repair Regen 2007;15:607-616.
11. Xiang SY, Dusaban SS, Brown JH. Lysophospholipid receptor activation of RhoA and lipid signaling pathways. Biochim Biophys Acta 2013;1831:213-222.
12. Pradere JP, Gonzalez J, Klein J, Valet P, Gres S, Salant D, Bascands JL, Saulnier-Blache JS, Schanstra JP. Lysophosphatidic acid and renal fibrosis. Biochim Biophys Acta 2008;1781:582-587.
13. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 2008;1781:513-518.
14. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010;50:157-186.
15. Tager AM. Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis. Am J Respir Cell Mol Biol 2012;47:563-565.
16. Tager AM, La Camera P, Shea BS, Campanella GS, Selman M, Zhao Z, Polosukhin V, Wain J, Karimi-Shah BA, Kim ND, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008;14:45-54.
17. Yin Z, Watsky MA. Chloride channel activity in human lung fibroblasts and myofibroblasts. Am J Physiol Lung Cell Mol Physiol 2005;288:L1110-L1116.
18. Shiomi T, Boudreault F, Padem N, Higashiyama S, Drazen JM, Tschumperlin DJ. Lysophosphatidic acid stimulates epidermal growth factor-family ectodomain shedding and paracrine signaling from human lung fibroblasts. Wound Repair Regen 2011;19:229-240.
19. Mio T, Liu X, Toews ML, Rennard SI. Lysophosphatidic acid augments fibroblast-mediated contraction of released collagen gels. J Lab Clin Med 2002;139:20-27.
20. Funke M, Zhao Z, Xu Y, Chun J, Tager AM. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am J Respir Cell Mol Biol 2012;46:355-364.
21. Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bundey RA, Prodanovich PC, Fagan P, Baccei CS, Santini AM, Hutchinson JH, et al. A novel, orally active LPA (1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol 2010;160:1699-1713.
22. 1/3 ameliorates lung fibrosis induced by irradiation. Biochem Biophys Res Commun 2011;409:7-13.
23. Pradere JP, Klein J, Gres S, Guigne C, Neau E, Valet P, Calise D, Chun J, Bascands JL, Saulnier-Blache JS, et al. LPA1 receptor activation promotes renal interstitial fibrosis. J Am Soc Nephrol 2007;18:3110-3118.
24. Tatler AL, Jenkins G. TGF-beta activation and lung fibrosis. Proc Am Thorac Soc 2012;9:130-136.
25. Lepparanta O, Sens C, Salmenkivi K, Kinnula VL, Keski-Oja J, Myllarniemi M, Koli K. Regulation of TGF-beta storage and activation in the human idiopathic pulmonary fibrosis lung. Cell Tissue Res 2012;348:491-503.
26. Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, McAnulty RJ, Sheppard D, Jenkins G. Lysophosphatidic acid induces alphaVbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha (Q). Am J Pathol 2009;174:1264-1279.
27. Zhao Y, Tong J, He D, Pendyala S, Evgeny B, Chun J, Sperling AI, Natarajan V. Role of lysophosphatidic acid receptor LPA2 in the development of allergic airway inflammation in a murine model of asthma. Respir Res 2009;10:114.
28. Huang LS, Berdyshev E, Mathew B, Fu P, Gorshkova IA, He D, Ma W, Noth I, Ma SF, Pendyala S, et al. Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis. FASEB J 2013;27:1749-1760.
29. Fu P, Murley JS, Grdina DJ, Birukova AA, Birukov KG. Induction of cellular antioxidant defense by amifostine improves ventilator-induced lung injury. Crit Care Med 2011;39:2711-2721.
30. Usatyuk PV, Singleton PA, Pendyala S, Kalari SK, He D, Gorshkova IA, Camp SM, Moitra J, Dudek SM, Garcia JG, et al. Novel role for nonmuscle myosin light chain kinase (MLCK) in hyperoxia-induced recruitment of cytoskeletal proteins, NADPH oxidase activation, and reactive oxygen species generation in lung endothelium. J Biol Chem 2012;287:9360-9375.
31. Huang LS, Kang JS, Kim MR, Sok DE. Oxygenation of arachidonoyl lysophospholipids by lipoxygenases from soybean, porcine leukocyte, or rabbit reticulocyte. J Agric Food Chem 2008;56:1224-1232.
32. Huang LS, Hung ND, Sok DE, Kim MR. Lysophosphatidylcholine containing docosahexaenoic acid at the Sn-1 position is anti-inflammatory. Lipids 2010;45:225-236.
33. Jeon ES, Kim JH, Ryu H, Kim EK. Lysophosphatidic acid activates TGFBIP expression in human corneal fibroblasts through a TGF-beta1-dependent pathway. Cell Signal 2012;24:1241-1250.
34. Sato M, Shegogue D, Hatamochi A, Yamazaki S, Trojanowska M. Lysophosphatidic acid inhibits TGF-beta-mediated stimulation of Type I collagen mRNA stability via an ERK-dependent pathway in dermal fibroblasts. Matrix Biol 2004;23:353-361.
35. Steele MP, Schwartz DA. Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu Rev Med 2013;64:265-276.
36. Castelino FV, Seiders J, Bain G, Brooks SF, King CD, Swaney JS, Lorrain DS, Chun J, Luster AD, Tager AM. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum 2011;63:1405-1415.
37. Fernandez IE, Eickelberg O. The impact of TGF-beta on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc 2012;9:111-116.
38. Otsuka M, Negishi Y, Aramaki Y. Involvement of phosphatidylinositol-3- kinase and ERK pathways in the production of TGF-beta1 by macrophages treated with liposomes composed of phosphatidylserine. FEBS Lett 2007;581:325-330.
39. Presser LD, McRae S, Waris G. Activation of TGF-beta1 promoter by hepatitis C virus-induced AP-1 and SP1: role of TGF-beta1 in hepatic stellate cell activation and invasion. PLoS ONE 2013;8:e56367.
40. Tokumura H, Umezawa A, Cao H, Sakamoto N, Imaoka Y, Ouchi A, Yamamoto K. Laparoscopic management of common bile duct stones: transcystic approach and choledochotomy. J Hepatobiliary Pancreat Surg 2002;9:206-212.
41. Oikonomou N, Mouratis MA, Tzouvelekis A, Kaffe E, Valavanis C, Vilaras G, Karameris A, Prestwich GD, Bouros D, Aidinis V. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol 2012;47:566-574.
42. Renzoni EA, Abraham DJ, Howat S, Shi-Wen X, Sestini P, Bou-Gharios G, Wells AU, Veeraraghavan S, Nicholson AG, Denton CP, et al. Gene expression profiling reveals novel TGFbeta targets in adult lung fibroblasts. Respir Res 2004;5:24.
43. Milara J, Navarro R, Juan G, Peiro T, Serrano A, Ramon M, Morcillo E, Cortijo J. Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition. Thorax 2012;67:147-156.
44. Kono Y, Nishiuma T, Nishimura Y, Kotani Y, Okada T, Nakamura S, Yokoyama M. Sphingosine kinase 1 regulates differentiation of human and mouse lung fibroblasts mediated by TGF-beta1. Am J Respir Cell Mol Biol 2007;37:395-404.
45. Shea BS, Brooks SF, Fontaine BA, Chun J, Luster AD, Tager AM. Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol 2010;43:662-673.
46. Dudek SM, Jacobson JR, Chiang ET, Birukov KG, Wang P, Zhan X, Garcia JG. Pulmonary endothelial cell barrier enhancement by sphingosine 1-phosphate: roles for cortactin and myosin light chain kinase. J Biol Chem 2004;279:24692-24700.
47. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, English D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by EDG-dependent cytoskeletal rearrangement. J Clin Invest 2001;108:689-701.
48. McVerry BJ, Peng X, Hassoun PM, Sammani S, Simon BA, Garcia JG. Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med 2004;170:987-993.
49. Van Nieuw Amerongen GP, Vermeer MA, Van Hinsbergh VW. Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol 2000;20:E127-E133.
50. Goetzl EJ, Kong Y, Voice JK. Cutting edge: differential constitutive expression of functional receptors for lysophosphatidic acid by human blood lymphocytes. J Immunol 2000;164:4996-4999.